Global Drugs for Schistosomiasis Sales Market Report 2021

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
The global average price of Drugs for Schistosomiasis is in the decreasing trend, from 62 USD/K Units in 2011 to 57 USD/K Units in 2015. With the situation of global economy, prices will be in decreasing trend in the following five years.

Market Analysis and Insights: Global Drugs for Schistosomiasis Market
The global Drugs for Schistosomiasis market was valued at US$ 82 in 2020 and will reach US$ 102.8 million by the end of 2027, growing at a CAGR of 3.8% during 2022-2027.

Global Drugs for Schistosomiasis Scope and Market Size
The global Drugs for Schistosomiasis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Schistosomiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Praziquantel
Oxamniquine
Other

Segment by Application
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum

The Drugs for Schistosomiasis market is analysed and market size information is provided by regions (countries). Segment by Application, the Drugs for Schistosomiasis market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals

Frequently Asked Questions